Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
eli lilly
8
×
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
8
×
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
cancer
fda
startups
teva pharmaceutical
abbvie
alzheimer's disease
amgen
cancer immunotherapy
deals
novartis
pfizer
What
drug
8
×
bio
roundup
approval
companies
fda
new
migraine
won
alzheimer’s
class
decades
nash
news
pharmaceutical
price
prices
therapies
week
year
acquisitions
acute
addresses
amgen
annual
approved
arguments
assessed
attention
big
biggest
biogen’s
biopharmaceutical
biotech
build
buy
candidates
causes
ceo
commercialized
Language
unset
Current search:
drug
×
biotech
×
" raleigh-durham blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines